VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 14, 2026
Stock Comparison
AbbVie Inc. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AbbVie Inc.
ABBV · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.
View ABBV analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: AbbVie Inc. leads (65 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
AbbVie Inc.
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Global
Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients
Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)
47.4%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
AbbVie Inc. strengths
Bristol-Myers Squibb Company strengths
Segment mix
AbbVie Inc. segments
Full profile >Immunology
Oligopoly
Oncology
Competitive
Neuroscience
Competitive
Aesthetics
Oligopoly
Eye Care
Competitive
Other Key Products
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.